Without experimental evidence demonstrating effects on amyloid-β aggregation, tau phosphorylation, synaptic protein expression, neuroinflammation markers, or cognitive outcomes in AD-relevant model systems, the therapeutic hypothesis remains purely computational, without empirical foundation. This evidence concerns the gene MAPT and Alzheimer disease.